medtech · 2019-01-04 · executive summary pitchdeck asia by asia tech podcast compiled in dec...

MEDTECH TRANSFORMING HUMAN LIFE & HEALTH CARE

PITCHDECK ASIA by ASIA TECH PODCAST

Website: www.pitchdeck.asia; email: [email protected];

http://www.pitchdeck.asia/

mailto:[email protected]

Executive Summary PitchDeck Asia by Asia Tech Podcast Compiled in Dec 2018

INDUSTRY:

• As per a Frost & Sullivan report in May 2018, global healthcare industry is estimated to touch US $1.85 Trillion in 2018 growing by 5% over last year.

• North America is leading contributor with 38.5% of global healthcare market. Asia-Pacific contributes 27.9% and Japan in APAC is single largest contributor at 9.4%. (Source: Frost & Sullivan Report)


MedTech Devices space is the 2nd largest contributor to Healthcare after Pharma & Biotechnology.

• Global market for MedTech Devices is estimated to grow to US $409.5 Billion by 2023. (Source: Medical Device Market Report - ReportLinker)

• APAC region, with more than 50% of the world’s population, is estimated to grow to a US $133 Billion MedTech market by 2020 overtaking European Union as the world’s second largest MedTech market after US. (Source: McKinsey)

• Singapore has a market size of US $1.8 Billion for MedTech Devices and is a major exporter with value of exports crossing US $19.2 Billion in 2018. (Source: Website - export.gov)

GROWTH OF STARTUPS IN HEALTH TECH:

Many new MedTech startups are popping up in Asia with increasing number of Asian governments supporting and investing in the healthcare sector.

As per Galen Growth Asia report,

• HeathTech in APAC saw funding exceed US $2.6 Billion in 2017 and total no. of deals executed were 230, double the number of 2016.

• The top 3 categories attracting most funding consistently are Medical Data & Analytics, Health Service Search and Telehealth/Remote monitoring.

• China, India and Singapore are the top markets in APAC for MedTech startups.

6 ASIAN MEDTECH STARTUPS:

We have covered 6 MedTech startups who featured in our PitchDeck Asia Show, here’s a Free crib sheet of entire discussion during the podcast.

• AUM Biosciences • Biorithm • NDR Medical Technology

• Rock Human Devices • Shapecrunch • Speedoc

STARTUPS FEATURED

Aum Biosciences: Founder - Vishal Doshiwatch the full show - http://www.pitchdeck.asia/vishal-doshi-aum-biosciences

Biorithm: Founder - Amrish Nairwatch the full show - http://www.pitchdeck.asia/amrish-nair-biorithm

NDR Medical Technology: Founder - Alan Gohwatch the full show - http://www.pitchdeck.asia/alan-goh-ndr-medical

Rock Human Devices: Founder - Stuart Kerrwatch the full show - http://www.pitchdeck.asia/stuart-kerr-rock-human-devices

Shapecrunch: Founder - Nitin Gandhiwatch the full show - http://www.pitchdeck.asia/nitin-gandhi-shapecrunch

Speedoc: Founder - Shravan Vermawatch the full show - http://www.pitchdeck.asia/shravan-verma-speedoc

FOUNDER: VISHAL DOSHI

Sector MedTech

Product Space Oncology Focused Biotechnology

Location Singapore

Founded 2018

Website aumbiosciences.com

Stage Pre-Series A Stage

CO-FOUNDER: DR. HARISH DAVE


MARKET:

• In 2018, Cancer will claim 9.6 million lives and there will be 18.1 million new cases, up from 8.2

million deaths and 14.1 million new cases in 2012. (Source: WHO)

• Nearly 50% of New cases and more than 50% of cancer deaths in 2018 is from Asia. (Source:

WHO)

• Median annual cost to patient of a new cancer drug launched in 2017 exceeded $150000 compared

to $79000 in 2013. (Source: IQVIA Report)

• Oncology therapeutics market in 2017 was $ 133 Billion growing from $ 96 Billion in 2013 and is

estimated to reach $ 200 Billion by 2022. (Source: IQVIA Report)

PROBLEM

• Research institutions are innovation hotbeds, but commercial potential could remain untapped due

to academic mindset focused on discovery leading to research assets sitting in the laboratories.

• Pharma companies choose their priority areas basis their current strategy, geographical priorities,

regulatory frameworks leading to a lot of research being deprioritized.

• Traditional biotech models focused on US & EU markets due to multiple reasons.

SOLUTION

• Acquires the high potential deprioritized assets by collaborating with the research institutions, global

pharma/large biotech companies.

• Undertake and de-risk clinical development until POC or post-POC and monetize de-risked

candidates for large stage development and commercialization.

3 Pillars in AUM BIOSCIENCES’ product approach –

1. Focus on small molecules to lower product costs for Asia, then take it to western markets.

2. Application of Precision Medicine

3. Digital Approach using AI to collect data for analysis.


REVENUE MODEL

• Multiple revenue streams via Clinical, Digital and Genomic data.

TEAM

• Founder team has 35+ years’ experience in the industry.

• The management team consists of members who are ex-Zicom Medtacc, UCL, Elsevier, NHS.

• Board of advisors - experienced in organizations like ThermoFisher, Citibank, Ranbaxy, Tsinghua

Berkeley Shenzhen, NUS, Cancer Science Institute.

FUNDING

• Raised an undisclosed amount in seed funding from a private bank.

• Looking for strategic partners with industry experience and usable network in the industry to

leverage.

MILESTONES

Thank you

Incorporated in Late 2018Partnering with

Research Institutions,

Pharma companies

Seed Funding by Private Bank

Pipeline of 5 small molecule assets by

2020

FOUNDER/DIRECTOR: AMRISH NAIR

Sector MedTech

Product Space Medical Signal Processing

Location Singapore

Founded 2015

Website Bio-rithm.com

Stage Pre-Series Angel round

CO-FOUNDER: PROF. DAVID FOO

CO-FOUNDER: PROF. PINA MARZILIANO


MARKET:

• As per 2012 report by NCBI, 165 million pregnancies across the globe. (Source: National Center for

Biotechnology Information)

• Royal Philips, a global leader in health technology, in an article on their company website stated

that up to 20 % of pregnancies worldwide are estimated to be “at risk”.

• 830 women die every day from preventable causes related to pregnancy and childbirth. 99% of all

these maternal deaths occur in developing countries. (Source: WHO)

• Global Fetal and Neonatal Care Equipment market is expected to grow from $ 7.32 Billion in 2016

to $ 11.86 Billion by 2022 with a CAGR of 8.3%. (Source: Stratistics MRC Report quoted on Reuters)

• Global Home Prenatal Monitoring devices market estimated to grow at 6.9% CAGR between 2018-

2022. (Source: Research and Markets Report, April 2018)

PROBLEM

• Pre-natal fetal monitoring system not evolved. There are few options for in-home devices, requires

trained user & frequent repositioning and has high inter-observer variability.

• High cost of frequent hospital visits in case of high-risk pregnancies which are on the rise.

SOLUTION

• Fetal monitoring system for pre-natal care at home using a mobile app, backed by a web platform

for patient health tracking, analysis, early diagnosis and timely feedback.

• Benefits of the Solutions -

o Biorithm wants to decentralize prenatal care by providing quality patient monitoring &

diagnostic care round the clock at home for the high-risk patients.

o Avoid many pregnancy complications & bring down costs.

o Provide automated objective metrics through their web application to junior doctors to

ensure quality care to their patients.


REVENUE MODEL

• Subscription based revenue from Biorithm’s Telehealth Solution (Proposed @USD 1400-2000 per

trimester or Pay-per use in developing countries).

• Licensing & Royalties from Biorithm’s Software Data Analysis (10-35%)

TEAM

• Founder team with 15+ years’ experience across E&E Engineering and Cardiology.

• Management team consists personnel from the field of engineering and health care, majority being

women in field of pregnancy care.

• Hospitals like Monash Health, Singapore General Hospital, NUH, Tan Tock Seng are their dedicated

partners.

FUNDING

• Currently raising S$ 500K at pre-money valuation of S$ 5Million (raised S$ 290K as on Nov 2018).

• Plan to raise additional S$ 3 Million next year in Series A for completing clinical trials, expand team,

get regulatory approvals and finalize design for product manufacturing.

• Previously raised S$ 550K in seed capital from Friends & Family, Angel investors.

• Spring Singapore and NTU have backed them with S$ 500K each as grants till date.

Thank you

JAN 2015 -JUL 2016ANGEL

INVESTORS S$ 130K

AUG 2016SPRING

POVS$ 500K

DEC 2016 -MAY 2017

ANGEL INVESTORS

S$ 420K

DEC 2017NTU

S$ 500K

NOV 2018PRE SERIES

S$ 500K

FEB 2019PLANNED

RAISES$ 3 M.

FOUNDER: ALAN GOH

Sector MedTech

Product Space Robotics & Imaging

Location Singapore

Founded 2014

Website ndrmedical.com

Stage Raising Series-A

CO-FOUNDER: DR. JASON NG


MARKET:

• 9.6 million Cancer deaths each year across the globe, most common being Lung & Breast Cancer.

(Source: WHO)

• In 2010, an estimate of annual economic cost of cancer was approximately US $1.16 Trillion,

economic impact significant and increasing since then. (Source: WHO)

• Global Biopsy market estimated at US $1.9 Billion in 2017, predicted to grow at 6.5% CAGR

between 2018-2024. (Source: Global Market Insights Report)

• Guidance systems contributed to 45% of the Biopsy market and will cross US $1 Billion market size

within the next 3 years. (Source: Global Market Insights Report)

• US contributes 48% of total biopsy devices sales across world, followed by Europe. Japan, China

& India major markets in APAC for biopsy devices. (Source: Global Market Insights Report)

PROBLEM

• Reliability of diagnosis is dependent on the accuracy of the biopsy, however, there can be

inaccuracy in percutaneous access due to difficulty involved while handling small tumors.

• Free hand alignment of the needle is highly skill dependent, can be time consuming with high

radiation exposure.

SOLUTION

• By combining Artificial Intelligence, Robotics and 3D image guidance, NDR has developed a robotic

automated needle positioning (ANT) system for minimally invasive surgery.

• Using this ANT, surgeons can reduce the complexity and increase the accuracy of the surgical

procedure.

• The AI driven robotic solution eases the requirement of high skills & experience for performing the

biopsy.


REVENUE MODEL

• Capital Equipment sales (Robots for performing procedure).

• Single use Consumables sales.

• Software License & Service Model.

TEAM

• The founder team has 20+ years’ experience in the industry.

• The management team consists of eminent doctors, professors of medicine & engineering from

organizations like Columbia University, Cambridge university, Carnegie Mellon, Malaya Medical

Center, NTU College, Tianjing University.

• Clinical partners include Singapore General Hospital, Tan Tock Seng hospital, University of Malaya

Medical Centre, Tianjin University.

FUNDING

• Currently raising S$ 6 Million for capital to enter US & China markets, get the necessary

certifications & regulatory approvals and for commercialization of the product.

• Looking for strategic investors, “smart money” who can bring industry knowledge & network

connections.

• Institutional seed funding partners till date are SGInnovate, INNOSPARKS, NTUitive.

• Enterprise Singapore provided the POC+POV grants.

Thank you

Incorporated in Late 2014

Research & Clinical

Trials

Early 2018 -Seed

Funding closed

Oct 2018 -Series A

Raise S$ 6 Million

Clinical Trial &

Commerc-ialization Q1 2020

FOUNDER: STUART KERR

Sector MedTech

Product Space MedTech Device for Hearing Aid

Location Singapore

Founded 2017

Website www.rockhumandevices.com

Stage Seed/Angel Stage

http://www.rockhumandevices.com/


MARKET:

• 466 Million people, including 34 Million children, suffer from disabling hearing loss and by 2050 the

number is estimated to increase to 900 Million people. (Source: WHO)

• Global hearing aids market size is expected to reach US $9.25 Billion by year 2023 from US $5.85

Billion in 2017, growing at a CAGR of 8%. (Source: Research and Markets Report on Hearing Aids)

• Unaddressed hearing loss poses an annual global cost of US $750 Billion. (Source: WHO)

PROBLEM

• 20-25% of the people having hearing loss suffer from conductive hearing loss and in most of these

cases the regular hearing aid devices do not help.

• Current solution of reconstructive surgery of the ear in cases of conductive hearing loss is very

expensive and the procedure is invasive and painful.

• Hearing Aid Devices are expensive ranging from US $1000-6000 leading to lower adoption.

(Source: Mordor Intelligence)

SOLUTION

• An external hearing aid device which is integrated with eyewear avoiding the need for invasive

surgical procedures. The product uses Bone Conduction Vibrators, electronics and audio

processing to help the users.

• Redefine perception about medical devices by offering hearing aid incorporated in a stylish line of

eyewear choices, hence helping the users overcome the awkwardness associated with wearing

traditional hearing aid devices.

REVENUE MODEL

• 1st Purchase - Product to be prescribed by Audiologists to patients.

• B2C model to sell subsequent products or upgrades/designs to the customer.


TEAM

• Stuart Kerr (Founder), has experience working in an MNC like Dyson and has handled roles in

complex engineering projects.

• Lean team by outsourcing tasks - One team member for software development and actively looking

for talent with engineering background for product development.

• Next year, a CEO with Industry experience to be brought in for heading business operations, while

Stuart heads engineering and product development.

FUNDING

• Two rounds of seed funding till date - S$ 105K and S$ 420K from VCs and Angels.

• 2nd round of S$ 420K to purchase Industrial 3D Printers for rapid prototyping and PCT

applications.

• Current investment gives the company 20 months’ runway.

• Plan for Pre-series A raise of S$ 2M by April 2019 – capital for patent applications, team

expansion including CEO and a certified manufacturing set-up.

MILESTONES

Thank you

STARTED IN MAY 2017

1st ROUND SEED FUNDING

FROM VCs S$ 105K

2nd ROUND SEED FUNDING FROM ANGELS

S$ 420K

PLAN TO RAISE PRE-SERIES A IN

APR 2019S$ 2M

MANUFACTURING SET-UP FOR

COMMERCIALIZATION

FOUNDER: NITIN GANDHI

Sector MedTech

Product Space 3D Printing MedTech Wearable

Location India

Founded 2015

Website shapecrunch.com

Stage Pre-Series Stage

Executive Summary By PitchDeck Asia from Asia Tech Podcast Compiled in Dec 2018

MARKET:

• As per a survey by American Podiatric Medical Association (APMA), 77% of US adults experience

foot problems.

• Global Foot insoles market alone is expected to grow to US $3.6 Billion by 2021, growing at the rate

of 7% for the period 2017-2021. (Source: Technavio Report on Business Wire)

• North & South America contributes 51.89%, Europe-Middle East-Africa contributes 32.64% and

APAC contributes 15.47% of the total global revenues. APAC fastest growing with expected CAGR

of 9% from 2017-2021. (Source: Technavio Report on Business Wire)

• As per Shapecrunch, total market size potential of US market alone basis a National Foot Health

Assessment-2012 commissioned by Institute for Preventive Foot Health is US $10 Billion

(Calculations at US $80 per unit). Targeting 15% market share will give US $1.5 Billion opportunity..

PROBLEM

• Foot problem leads to Back Pain, Knee Pain, Hip Pain, Ankle Instability, Osteoarthritis and several

other problems.

• Orthotics despite being better solution, specialists recommend over the counter products – may not

be the exact fit for addressing the pain.

• Current special custom foot products are expensive due to expensive scanners, with longer

assessment time for customization and not completely accurate.

SOLUTION

• Foot scanning and pressure sensing via a smartphone – Just needs 3 pictures of both foot along

with details such as Pain areas, Activity level, shoe size, shoe type and Doctor’s prescription.

• 3D model generated from the app is 3D printed to create the custom foot product.

• Process time: 7-10 mins to scan and 4 hours to 3D print the whole pair.

• Possibility of developing specialized foot products basis gait, pressure and posture analysis.

Executive Summary By PitchDeck Asia from Asia Tech Podcast Compiled in Dec 2018

REVENUE MODEL

• The software application is provided to Doctors and Medical Health professionals for use –

Prescription based model. Final product shipped and billed to patients.

• B2C model to sell subsequent products or for future non-medical usage like sports shoes insoles.

TEAM

• Young team of engineer founders working together for 3 years.

• Experienced Doctors in the advisory panel for the Indian & Singapore market. Seeking similar

partnerships in US market.

FUNDING

• Currently raising US $750K to give 24-36-month runway. Prefer strategic investors with

experience in the medical field and network in the medical business community.

• Funding raise – Entry into US market, Convert product onto an online platform, availability of

future scanning services for gait, posture & pressure analysis on the single mobile application.

• Products for sale in India & Singapore – Already achieved break-even in both countries.

Thank you

FOUNDER: DR. SHRAVAN VERMA

Sector MedTech

Product Space On Call Doctor @Home

Location Singapore

Founded 2017

Website speedoc.com

Stage Series A Stage

PitchDeck Asia by Asia Tech Podcast

MARKET:

• 1 million patients visit the A&E departments of government restructured hospitals each year. Figures

go up almost 5 times when specialist outpatient clinics are included. (Source: singstat.gov.sg)

• Less than 50% of the A&E department patients require hospitalization. (Source: singstat.gov.sg)

• Citizens aged 65 and above increased from 220,000 in 2000 to 440,000 in 2015, expected to reach

900,000 by 2030. (Source: Ministry of Communications and Information – www.gov.sg website

news article on impact of ageing population.)

PROBLEM

• Overcrowding in the A&E due to non-critical patient’s visit leads to long waiting times at hospitals.

• Difficulty in taking elderly/immobile patients to clinics, inconvenient setting in hospital’s waiting

rooms for them. Ageing population will lead to higher healthcare visits to hospitals/clinics.

• Lack of medical options after hours other than hospitals.

• Current House call services inaccessible and inefficient, technologically outdated.

SOLUTION

• One-Tap Request over mobile for 24/7 Medical House calls by vetted doctors.

• Advanced medical care at home with on-spot medications & treatment.

• All-inclusive support system for the empaneled doctors with complete backend medical logistics

network.

• Geo-location based mobile application for efficient system of on-call doctors.

• Partner laboratory facilities for fast medical checkups in required cases.

REVENUE MODEL

• B2C - Flat charges from patients.

http://www.gov.sg/

PitchDeck Asia by Asia Tech Podcast

TEAM

• Dr. Shravan Verma, founder & CEO, is a practicing medical doctor. Empaneled doctors are all

vetted, fully licensed and registered medical doctors with years of experience.

• Management team consists of medical professionals with 10+ years’ experience in nursing as well

as a Strategic Development Director with 30 years’ experience as Banker, Investor & Entrepreneur.

• Advisors include Dr. Zubin Daruwalla (Director & Healthcare Lead, PwC), Ernest Xue (Founder &

CEO, Slate Alt), Kevin Harrington (Original Shark on “Shark Tank”, Founder of As Seen on TV)

• Partnership with Parkway Health Laboratory, The HouseCall GP, MHC.

FUNDING

• Currently raising Series-A fund to the tune of S$ 4-5 million.

• Fund raise - Scale up Singapore with more empaneled doctors on permanent rolls, increase

marketing, invest in medical equipment & medications, expand into neighboring markets.

• Future Directions post funding – AI & Machine learning algorithms for medications & equipment

prediction, Mobile Solutions (X-rays, CT Scans, MRI, Stroke & Accident units), IoT Medical

devices for Triaging and Monitoring Patient data.

Thank you

FOUNDED IN 2017

SEED FUNDING - UNDISCLOSED

AMOUNT

START RAISE OF SERIES-A FOR

S$ 4-5 MILLION SEPT 2018

SCALE SINGAPORE, "SPEEDMED"

EXPANSION INTO OTHER MARKETS -

2019

by Asia Tech Podcast

We are on a mission to find Asia’s best startups. We want to give Asia’s exciting tech ecosystem a chance to tell their story in the long form – a format that goes

deeper than the 10-minute Demo day or Pitch competition.

Enter your startup and get featured on Pitchdeck Asia

Available on –

P.S. – You know a startup who should be on the Pitchdeck Asia show? >>> You can submit entries to the show at www.pitchdeck.asia/enter

http://www.pitchdeck.asia/enter



medtech · 2019-01-04 · executive summary pitchdeck asia by asia tech podcast compiled in dec...

Documents